menu
    • menu

    Company profile for Biogen

    NEW Drugs in Dev: 83
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 1978 by a small group of visionary scientists, Biogen helped pioneer the biotechnology industry. Today, we are one of the oldest independent biotechnology companies in the world. For close to four decades, hundreds of thousands of people around the world living with serious illnesses have benefited from innovative and important medicines developed by the people of Biogen. We are proud of the role we have played in a...
    Founded in 1978 by a small group of visionary scientists, Biogen helped pioneer the biotechnology industry. Today, we are one of the oldest independent biotechnology companies in the world. For close to four decades, hundreds of thousands of people around the world living with serious illnesses have benefited from innovative and important medicines developed by the people of Biogen. We are proud of the role we have played in advancing the field of biotechnology and helping patients — and are building on this legacy of great science and discovery as we pursue increasingly complex challenges.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BiogenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    225 Binney Street Cambridge, MA 02142
    Telephone
    Telephone
    +1 781-464-2000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biogen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biogen-/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/biogen

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ICMD China

    ICMD China

    Not Confirmed

    envelop Contact Supplier

    ICMD China

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    With Trial Looming, Biogen And Investors Settle Aduhelm Claims
    With Trial Looming, Biogen And Investors Settle Aduhelm Claims

    08 Apr 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biogen-settles-investor-lawsuit-its-messaging-alzheimers-drug

    FIERCE PHARMA
    08 Apr 2026
    Share Share
    Biogen Links Up With Alloy Platform To Boost ASO Drug Development
    Biogen Links Up With Alloy Platform To Boost ASO Drug Development

    07 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/biogen-links-alloy-platform-boost-aso-drug-development

    FIERCE BIOTECH
    07 Apr 2026
    Share Share
    Biogen Bets on $5.6 Billion buyout of Apellis
    Biogen Bets on $5.6 Billion buyout of Apellis

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265288/0/en/Biogen-to-Acquire-Apellis-Enhancing-the-Company-s-Growth-Portfolio-in-Immunology-and-Rare-Disease-Bolstering-Growth-Outlook-and-Accelerating-Expansion-into-Nephrology.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    FDA Approves New High Dose Regimen of SPINRAZA for SMA
    FDA Approves New High Dose Regimen of SPINRAZA for SMA

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264519/0/en/FDA-Approves-New-High-Dose-Regimen-of-SPINRAZA-nusinersen-for-Spinal-Muscular-Atrophy.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Biogen's Litifilimab Sparkles In Midphase Lupus Trial
    Biogen's Litifilimab Sparkles In Midphase Lupus Trial

    30 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/biogens-litifilimab-sparkles-midphase-lupus-trial-raising-hopes-pivotal-readout

    FIERCE BIOTECH
    30 Mar 2026
    Share Share
    Biogen Announces Phase 2 Results for Litifilimab in Lupus in AAD
    Biogen Announces Phase 2 Results for Litifilimab in Lupus in AAD

    28 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/28/3264201/0/en/Biogen-Announces-Second-Positive-Phase-2-Litifilimab-Trial-in-Cutaneous-Lupus-Erythematosus-at-2026-American-Academy-of-Dermatology-Annual-Meeting-Showing-a-Significant-Reduction-i.html

    GLOBENEWSWIRE
    28 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Biogen and get a quotation

    Biogen is a supplier offers 3 products (APIs, Excipients or Intermediates).

    Find a price of MURINE MONOCLONAL ANTIBODY (2B8) TO CD20 bulk offered by Biogen

    Find a price of HUMANIZED MONOCLONAL ANTIBODY (IDEC-131) (CHO CELLS, IDEC) TO CD40L (CD 154) bulk offered by Biogen

    Find a price of IDEC-114 (GALIXIMAB);CHEMERIC (MACAQUE/HUMAN) MONOCLONAL ANTIBODY TO CD80 (B7.1) bulk offered by Biogen

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search